https://orcid.org/0000-0001-9855-878X
Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
David A Fraser, Stephen A Harrison & Detlef Schuppan. (2022) Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH. Expert Opinion on Investigational Drugs 31:12, pages 1269-1278.
Read now
Read now
Articles from other publishers (45)
Annalisa Filtz, Siddhant Parihar, Garred S. Greenberg, Christine M. Park, Andrea Scotti, Daniel Lorenzatti, Juan J Badimon, Daniel E. Soffer, Peter P. Toth, Carl J. Lavie, Vera Bittner, Salim S. Virani & Leandro Slipczuk. (2024) New approaches to triglyceride reduction: Is there any hope left?. American Journal of Preventive Cardiology 18, pages 100648.
Crossref
Crossref
Bibiche den Hollander, Marion M. Brands, Ilse J.M. Nijhuis, Lous J.A.E. Doude van Troostwijk, Peter van Essen, Geesje H. Hofsteenge, Bart G. Koot, Annelieke R. Müller, Laura A. Tseng, Erik S.G. Stroes, Peter M. van de Ven, Albert Wiegman & Clara D.M. van Karnebeek. (2024) Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen. Molecular Genetics and Metabolism 142:1, pages 108347.
Crossref
Crossref
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms & Rosie Yu. (2024) Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clinical and Translational Science 17:4.
Crossref
Crossref
Merve Yoldas Celik, Ebru Canda, Havva Yazici, Fehime Erdem, Ayse Yuksel Yanbolu, Yasemin Atik Altinok, Erhan Pariltay, Haluk Akin, Sema Kalkan Ucar & Mahmut Coker. (2024) Long-term clinical outcomes and management of hypertriglyceridemia in children with Apo-CII deficiency. Nutrition, Metabolism and Cardiovascular Diseases.
Crossref
Crossref
Alejandro Gugliucci. (2024) The chylomicron saga: time to focus on postprandial metabolism. Frontiers in Endocrinology 14.
Crossref
Crossref
Heyang Zhang, Jo Vandesompele, Kevin Braeckmans, Stefaan C. De Smedt & Katrien Remaut. (2024) Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity. Chemical Society Reviews 53:1, pages 317-360.
Crossref
Crossref
Majid Mufaqam Syed-AbdulLili Tian & Gary F. Lewis. (2023) Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology 43:11, pages 2133-2142.
Crossref
Crossref
Kate Williams, Georgina Tickler, Pedro Valdivielso, Jordi Alonso, Montserrat Vera-Llonch, Laia Cubells & Sarah Acaster. (2023) Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience. Orphanet Journal of Rare Diseases 18:1.
Crossref
Crossref
Zahraa Qusairy, Anne Gangloff & Shuk On Annie Leung. (2023) Dysregulation of Cholesterol Homeostasis in Ovarian Cancer. Current Oncology 30:9, pages 8386-8400.
Crossref
Crossref
Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz & Beata Franczyk. (2023) Advances in Treatment of Dyslipidemia. International Journal of Molecular Sciences 24:17, pages 13288.
Crossref
Crossref
Danielle Rasooly, Gina M. Peloso, Alexandre C. Pereira, Hesam Dashti, Claudia Giambartolomei, Eleanor Wheeler, Nay Aung, Brian R. Ferolito, Maik Pietzner, Eric H. Farber-Eger, Quinn Stanton Wells, Nicole M. Kosik, Liam Gaziano, Daniel C. Posner, A. Patrícia Bento, Qin Hui, Chang Liu, Krishna Aragam, Zeyuan Wang, Brian Charest, Jennifer E. Huffman, Peter W. F. Wilson, Lawrence S. Phillips, John Whittaker, Patricia B. Munroe, Steffen E. Petersen, Kelly Cho, Andrew R. Leach, María Paula Magariños, John Michael Gaziano, Claudia Langenberg, Yan V. Sun, Jacob Joseph & Juan P. Casas. (2023) Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure. Nature Communications 14:1.
Crossref
Crossref
Rafael H. Isaac, Deyanira Gonzalez-Devia, Carlos O. Mendivil & Edgardo Chapman. (2023) Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen. Frontiers in Allergy 4.
Crossref
Crossref
Alan Jones, Katherine Peers, Anthony S. Wierzbicki, Radha Ramachandran, Michael Mansfield, Charlotte Dawson, Antonio Ochoa-Ferraro, Handrean Soran, Fiona Jenkinson, Ian McDowell, Paul Downie, Paul Hamilton & Richard D Jones. (2023) Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS). Atherosclerosis 375, pages 67-74.
Crossref
Crossref
Yan Zhou, Xueping Zhu, Huan Wang, Chenglin Duan, Hanming Cui, Jingjing Shi, Shuai Shi, Guozhen Yuan & Yuanhui Hu. (2023) The Role of VEGF Family in Lipid Metabolism. Current Pharmaceutical Biotechnology 24:2, pages 253-265.
Crossref
Crossref
Eduardo Esteban & Daniel Aimone. (2023) Familial chylomicronemia syndrome: A comprehensive clinical and genetic approach. Journal of Inborn Errors of Metabolism and Screening 11.
Crossref
Crossref
Satheesh Kumar, Lewis E. Fry, Jiang-Hui Wang, Keith R. Martin, Alex W. Hewitt, Fred K. Chen & Guei-Sheung Liu. (2023) RNA-targeting strategies as a platform for ocular gene therapy. Progress in Retinal and Eye Research 92, pages 101110.
Crossref
Crossref
Arshag D. Mooradian. 2023. The Diabetes Textbook. The Diabetes Textbook
645
656
.
Alexander Curreri, Disha Sankholkar, Samir Mitragotri & Zongmin Zhao. (2022)
RNA
therapeutics in the clinic
. Bioengineering & Translational Medicine 8:1.
Crossref
Crossref
Anthony S Wierzbicki, Eun Ji Kim, Oluwayemisi Esan & Radha Ramachandran. (2022) Hypertriglyceridaemia: an update. Journal of Clinical Pathology 75:12, pages 798-806.
Crossref
Crossref
Daniele Tramontano, Simone Bini, Laura D’Erasmo & Marcello Arca. (2022) Recent Apolipoprotein CIII trials. Current Opinion in Lipidology 33:6, pages 309-318.
Crossref
Crossref
Toufik Abdul-Rahman, Syed Muhammad Awais Bukhari, Emiliano Cantu Herrera, Wireko Andrew Awuah, Jannel Lawrence, Heloisa de Andrade, Neal Patel, Rohan Shah, Raheel Shaikh, Camilo Andrés Avendaño Capriles, Sebahat Ulusan, Shahzaib Ahmad, Anna Chiara Corriero, Adriana C. Mares, Akshay Goel, Adrija Hajra, Dhrubajyoti Bandyopadhyay & Rahul Gupta. (2022) Lipid Lowering Therapy: An Era Beyond Statins. Current Problems in Cardiology 47:12, pages 101342.
Crossref
Crossref
Angelo B. Cefalù, Laura D'Erasmo, Gabriella Iannuzzo, Davide Noto, Antonina Giammanco, Anna Montali, Alberto Zambon, Francesco Forte, Patrizia Suppressa, Stefano Giannini, Carlo M. Barbagallo, Antonina Ganci, Emilio Nardi, Federica Vernuccio, Rosalia Caldarella, Marcello Ciaccio, Marcello Arca & Maurizio Averna. (2022) Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis 359, pages 13-19.
Crossref
Crossref
Ursa Sustar, Urh Groselj, Sabeen Abid Khan, Saeed Shafi, Iqbal Khan, Jernej Kovac, Barbara Jenko Bizjan, Tadej Battelino & Fouzia Sadiq. (2022) A homozygous variant in the GPIHBP1 gene in a child with severe hypertriglyceridemia and a systematic literature review. Frontiers in Genetics 13.
Crossref
Crossref
Miklós Bege & Anikó Borbás. (2022) The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides. Pharmaceuticals 15:8, pages 909.
Crossref
Crossref
Amanda J Berberich & Robert A Hegele. (2022) A Modern Approach to Dyslipidemia. Endocrine Reviews 43:4, pages 611-653.
Crossref
Crossref
Yonglang Cheng, Tongxi Li, Peng Tan, Yichao Du, Zhiwei Huang, Hao Shi, Tianying Cai, Yifan Chen & Wenguang Fu. (2022) Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis. Endocrine 76:2, pages 253-262.
Crossref
Crossref
Bhuvana Sunil & Ambika P. Ashraf. (2022) Childhood Hypertriglyceridemia: Is It Time for a New Approach?. Current Atherosclerosis Reports 24:4, pages 265-275.
Crossref
Crossref
Genovefa Kolovou, Vana Kolovou & Niki Katsiki. (2022) Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia. Journal of Clinical Medicine 11:4, pages 982.
Crossref
Crossref
Ioannis Parthymos, Michael S. Kostapanos, George Liamis & Matilda Florentin. (2022) Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia. Journal of Cardiovascular Development and Disease 9:2, pages 42.
Crossref
Crossref
Laura Valenzuela-Vallejo, Daniela Meléndrez-Vásquez, Paola Durán-Ventura, Carolina Rivera-Nieto, Adriana Lema & Monica Fernandez. (2022) Severe hypertriglyceridemia as a cause of necrotizing pancreatitis in a pediatric patient with familial hyperchylomicronemia syndrome: A case report. SAGE Open Medical Case Reports 10, pages 2050313X2211099.
Crossref
Crossref
Thomas M. Rupp & Hagen Cramer. 2022. RNA Therapeutics. RNA Therapeutics
263
320
.
Alireza Shahryari, Zahra Nazari, Marie Saghaeian Jazi, Fatemeh Hashemi-Shahraki, Katharina Wißmiller, Weiwei Xu, Ingo Burtscher & Heiko Lickert. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
326
368
.
Pia Laitinen, Tiia A. Turunen & Mikko P. Turunen. 2022. Biotechnologies for Gene Therapy. Biotechnologies for Gene Therapy
45
59
.
Alexandra Thajer, Gabriele Skacel, Charlotte de Gier & Susanne Greber-Platzer. (2021) The Effect of a Fat-Restricted Diet in Four Patients with Familial Chylomicronemia Syndrome: A Long-Term Follow-Up Study. Children 8:11, pages 1078.
Crossref
Crossref
Robert S. Rosenson, Aleesha Shaik & Wenliang Song. (2021) New Therapies for Lowering Triglyceride-Rich Lipoproteins. Journal of the American College of Cardiology 78:18, pages 1817-1830.
Crossref
Crossref
Manish Pandey, Divya Ojha, Sakshi Bansal, Ambadas B. Rode & Geetanjali Chawla. (2021) From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine 81, pages 101003.
Crossref
Crossref
Julieta Lazarte, Jian Wang, Adam D. McIntyre & Robert A. Hegele. (2021) Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2. Journal of Clinical Lipidology 15:5, pages 653-657.
Crossref
Crossref
Nolwenn Tessier, Fatma Moawad, Nada Amri, Davide Brambilla & Catherine Martel. (2021) Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine. Pharmaceutics 13:8, pages 1200.
Crossref
Crossref
Marcio H. Miname, Viviane Z. Rocha & Raul D. Santos. (2021) The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?. Current Atherosclerosis Reports 23:8.
Crossref
Crossref
Oluwayemisi Esan & Anthony S. Wierzbicki. (2021) Triglycerides and cardiovascular disease. Current Opinion in Cardiology 36:4, pages 469-477.
Crossref
Crossref
Aleesha Shaik & Robert S. Rosenson. (2021) Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. Cardiovascular Drugs and Therapy 35:3, pages 677-690.
Crossref
Crossref
Radu Sascău, Alexandra Clement, Rodica Radu, Cristina Prisacariu & Cristian Stătescu. (2021) Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review. Nutrients 13:6, pages 1774.
Crossref
Crossref
Hironori Adachi, Martin Hengesbach, Yi-Tao Yu & Pedro Morais. (2021) From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies. Biomedicines 9:5, pages 550.
Crossref
Crossref
Zhili Tian, Guohui Liang, Kunli Cui, Yayu Liang, Qun Wang, Shuangyu Lv, Xiaoxia Cheng & Lei Zhang. (2021) Insight Into the Prospects for RNAi Therapy of Cancer. Frontiers in Pharmacology 12.
Crossref
Crossref
Bhuvana Sunil, Christy Foster, Don P. Wilson & Ambika P. Ashraf. (2021) Novel therapeutic targets and agents for pediatric dyslipidemia. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882110583.
Crossref
Crossref